<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87519">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02133651</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00069524</org_study_id>
    <nct_id>NCT02133651</nct_id>
  </id_info>
  <brief_title>Mucosal Versus Fecal Microbiota in FMT</brief_title>
  <official_title>Characterization of the Microbial Genomics of Fecal Bacteriotherapy (FBT): Intestinal Microbiota Transplantation (IMT) for Recurring Clostridium Difficile</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clostridium difficile infection is the most common cause of antibiotic-associated diarrhea.
      Treatment of this infection usually occurs using other antibiotics, but many individuals
      have persistent diarrhea and multiple relapses. Fecal Transplant (FMT), or Intestinal
      Microbiota Transplantation, (IMT) has been shown to be efficacious when administered after
      treatment for C. difficile. This study will involve taking biopsies from patients during
      their FMT/IMT via colonoscopy, and determine if there are differences in the mucosal flora
      as compared to the stool flora. The investigators hope to discover the critical parts of a
      healthy microbiota.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 20 subjects with at least one relapse of Clostridium difficile infection
      undergoing Intestinal Microbiota Transplantation via colonoscopy will be recruited in this
      study. The patients will produce a stool specimen at the time of colonoscopy and a biopsy
      will be obtained during the colonoscopy.  At 2 weeks and 10 weeks, stool specimens and
      anoscopy will be collected to be tested for C. difficile polymerase chain reaction (PCR) and
      the fecal microbiota. Subjects will be referred from all locations of Emory Healthcare.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>The proportion of subjects who experience resolution of diarrhea associated with C. difficile infection without relapse 2 weeks and 10 weeks post Intestinal Microbiota Transplantation (IMT)</measure>
    <time_frame>10 weeks post IMT</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Clostridium Difficile</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Fecal matter from the consented donor, consented recipient at 3 time points will be stored
      in a -80 freezer.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Clostridium difficile infection at least twice and will be undergoing
        intestinal microbiota transplantation (IMT) via a colonoscopy for treatment from Emory
        University Hospital and Emory University Midtown.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inpatient or outpatient adults, age ≥18

          -  Have had at least 1 relapse of C. difficile

          -  Patients who have had previous FMT

        Exclusion Criteria:

          -  Pregnant or breastfeeding

          -  Critically or acutely ill (Fever will be defined as a documented temperature &gt;37.8°C)

          -  Ileus or toxic megacolon

          -  Unable to give consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colleen S. Kraft, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Colleen S. Kraft, MD</last_name>
    <phone>404-712-8889</phone>
    <email>colleen.kraft@emory.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen S. Kraft, MD</last_name>
      <phone>404-712-8889</phone>
      <email>colleen.kraft@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Colleen S. Kraft, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Friedman-Moraco RJ, Mehta AK, Lyon GM, Kraft CS. Fecal microbiota transplantation for refractory Clostridium difficile colitis in solid organ transplant recipients. Am J Transplant. 2014 Feb;14(2):477-80. doi: 10.1111/ajt.12577. Epub 2014 Jan 16.</citation>
    <PMID>24433460</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 6, 2014</lastchanged_date>
  <firstreceived_date>May 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Colleen S Kraft MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Clostridium difficile</keyword>
  <keyword>Intestinal Microbiota Transplantation</keyword>
  <keyword>Diarrhea</keyword>
  <keyword>Fecal Microbiota Transplant</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
